About Amneal Pharmaceuticals, Inc.
https://www.amneal.comAmneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE.
CEO
Chirag K. Patel
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 139
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:17.95M
Value:$237.9M
TPG GROUP HOLDINGS (SBS) ADVISORS, INC.
Shares:16.21M
Value:$214.83M
BLACKROCK, INC.
Shares:14.07M
Value:$186.48M
Summary
Showing Top 3 of 284
About Amneal Pharmaceuticals, Inc.
https://www.amneal.comAmneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $784.51M ▲ | $274.09M ▲ | $2.37M ▼ | 0.3% ▼ | $0.01 ▼ | $111.66M ▼ |
| Q2-2025 | $724.51M ▲ | $174.88M ▲ | $22.42M ▲ | 3.09% ▲ | $0.07 ▲ | $176.93M ▲ |
| Q1-2025 | $695.42M ▼ | $155.54M ▼ | $12.2M ▲ | 1.75% ▲ | $0.04 ▲ | $154.58M ▲ |
| Q4-2024 | $730.52M ▲ | $187.08M ▲ | $-31.08M ▼ | -4.25% ▼ | $-0.1 ▼ | $112.47M ▼ |
| Q3-2024 | $702.47M | $180.75M | $-156K | -0.02% | $-0 | $139.9M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $201.25M ▲ | $3.6B ▲ | $3.71B ▲ | $-109.46M ▲ |
| Q2-2025 | $81.19M ▲ | $3.42B ▲ | $3.47B ▲ | $-112.53M ▲ |
| Q1-2025 | $59.19M ▼ | $3.37B ▼ | $3.42B ▼ | $-131.67M ▼ |
| Q4-2024 | $112.42M ▲ | $3.5B ▲ | $3.55B ▲ | $-109.27M ▼ |
| Q3-2024 | $74.01M | $3.46B | $3.49B | $-93.43M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $18.13M ▼ | $118.45M ▲ | $-22.46M ▲ | $59.44M ▲ | $154.79M ▲ | $103.4M ▲ |
| Q2-2025 | $35.61M ▲ | $83.82M ▲ | $-26.55M ▼ | $-41.69M ▼ | $15.42M ▲ | $57.32M ▲ |
| Q1-2025 | $24.62M ▲ | $7.41M ▼ | $-17.8M ▼ | $-39.17M ▲ | $-50.03M ▼ | $-10.91M ▼ |
| Q4-2024 | $-20.74M ▼ | $118.08M ▼ | $-16.06M ▲ | $-61.2M ▲ | $40.08M ▲ | $95.01M ▼ |
| Q3-2024 | $11.76M | $141.77M | $-20.71M | $-92.35M | $28.72M | $121.06M |
Revenue by Products
| Product | Q3-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Amneal Specialty Pharma Segment | $120.00M ▲ | $110.00M ▼ | $130.00M ▲ | $130.00M ▲ |
 Specialty Segment | $0 ▲ | $110.00M ▲ | $0 ▼ | $0 ▲ |
 Generics Segment | $430.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
CEO
Chirag K. Patel
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 139
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:17.95M
Value:$237.9M
TPG GROUP HOLDINGS (SBS) ADVISORS, INC.
Shares:16.21M
Value:$214.83M
BLACKROCK, INC.
Shares:14.07M
Value:$186.48M
Summary
Showing Top 3 of 284